• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Curr Opin Microbiol . Cardiac damage and tropism of severe acute respiratory syndrome coronavirus 2

tetano

Editor, Senior Moderator
Curr Opin Microbiol


. 2024 Feb 22:78:102437.
doi: 10.1016/j.mib.2024.102437. Online ahead of print. Cardiac damage and tropism of severe acute respiratory syndrome coronavirus 2

Melina Tangos[SUP] 1 [/SUP], Muhammad Jarkas[SUP] 1 [/SUP], Ibrahim Akin[SUP] 2 [/SUP], Ibrahim El-Battrawy[SUP] 3 [/SUP], Nazha Hamdani[SUP] 4 [/SUP]



Affiliations
Abstract

Until now, the World Health Organization registered over 771 million cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection worldwide, of which 6.97 million resulted in death. Virus-related cardiovascular events and pre-existing heart problems have been identified as major contributing factors to global infection-related morbidity and mortality, emphasizing the necessity for risk assessment and future prevention. In this review, we highlight cardiac manifestations that might arise from an infection with SARS-CoV-2 and provide an overview of known comorbidities that worsen the outcome. Additionally, we aim to summarize the therapeutic strategies proposed to reverse virus-associated myocardial damage, which will be further highlighted in this review, with an outlook to successful recovery and prevention.


 
Back
Top Bottom